Flax Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 08-11-2024
- Paid Up Capital ₹ 50.00 K
as on 08-11-2024
- Company Age 3 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.90 Cr
as on 08-11-2024
- Revenue %
(FY 2023)
- Profit 4290.89%
(FY 2023)
- Ebitda -57645.43%
(FY 2023)
- Net Worth 69351.87%
(FY 2023)
- Total Assets 383972.77%
(FY 2023)
About Flax Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 50.00 K .
The company currently has active open charges totaling ₹8.90 Cr.
Rekhaben Suthar, Rajni Gaudani, Hetal Abhay, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239MH2021PTC359917
- Company No.
359917
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 May 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Raigarh, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Flax Laboratories?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajni Gaudani  | Director | 05-May-2021 | Current |
| Rekhaben Suthar | Director | 05-May-2021 | Current |
| Hetal Abhay | Director | 05-May-2021 | Current |
| Bharatbhai Suthar | Director | 28-Jul-2023 | Current |
Financial Performance of Flax Laboratories.
Flax Laboratories Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 4290.89% increase in profit. The company's net worth Soared by an impressive increase of 69351.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Flax Laboratories?
Unlock access to Flax Laboratories's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Kyana Labs Private LimitedActive 1 year 9 monthsRekhaben Suthar and Bharatbhai Suthar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 20 Apr 2023 | ₹8.90 Cr | Open |
How Many Employees Work at Flax Laboratories?
Unlock and access historical data on people associated with Flax Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Flax Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Flax Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
